Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | 0.00% | +11.11% | +12.90% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
Financials (USD)
Sales 2024 * | 189M | Sales 2025 * | 164M | Capitalization | 293M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -70M | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.78 x |
P/E ratio 2024 * |
-4.77
x | P/E ratio 2025 * |
-4.42
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.33% |
Latest transcript on Akebia Therapeutics, Inc.
1 day | -6.04% | ||
1 week | +11.11% | ||
Current month | +11.11% | ||
1 month | -6.04% | ||
3 months | -15.15% | ||
6 months | +28.44% | ||
Current year | +12.90% |
Managers | Title | Age | Since |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 13-06-30 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 22-03-31 |
Michel Dahan
COO | Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 18-12-11 |
Adrian Adams
CHM | Chairman | 73 | 18-12-11 |
Director/Board Member | 65 | 21-02-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 1.4 | 0.00% | 2 831 555 |
24-05-07 | 1.4 | -6.04% | 4,088,622 |
24-05-06 | 1.49 | +8.76% | 2,336,106 |
24-05-03 | 1.37 | +5.38% | 3,117,001 |
24-05-02 | 1.3 | +4.84% | 2,500,275 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.90% | 293M | |
+0.82% | 106B | |
+8.33% | 23.47B | |
-13.89% | 21.9B | |
-6.08% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B | |
+327.78% | 8.78B |
- Stock Market
- Equities
- AKBA Stock